Shareholders Filed a Lawsuit Against Alto Neuroscience for Misleading Drug Efficacy Claims

Court: N.D. California

Case: 3:25-cv-06105

On July 21, 2025, ANRO shareholders have filed a class action against Alto Neuroscience, accusing it of misleading investors about the clinical prospects of its lead drug, ALTO-100.

What is this lawsuit about?

Between February 1, 2024, and October 22, 2024, Alto promoted ALTO-100 as a breakthrough in precision psychiatry for major depressive disorder (MDD), emphasizing biomarker-linked efficacy. However, on October 22, 2024, the company revealed that ALTO-100 had failed its Phase 2b trial, showing no significant difference from placebo on its primary endpoint.

Following this, ANRO crashed 69.99%, erasing most of the value from its recent $119.6M IPO.

What can you do to recover your losses now?

We’re keeping track of all updates and will notify ANRO investors about potential recovery.

More than 600 companies are currently facing securities class action lawsuits, and over 100 are already paying settlements. Connect your brokerage account to automatically check which ones you may have missed.